P53 in cancer: a paradigm for modern management of cancer

R.J.C. Steele, D.P. Lane

    Research output: Contribution to journalArticlepeer-review

    50 Citations (Scopus)


    The p53 tumour suppressor gene is thought to be central in protecting against the development of cancer, and this article reviews current understanding of its function and potential clinical significance. Information for this review was obtained from previous review articles, references cited in original papers, a Pubmed search of the last twelve months' literature and by scanning the latest issues of relevant journals. P53 can be described as a stress response gene, its product (the p53 protein) acting to induce apoptosis or cell-cycle arrest in response to DNA damage, thereby maintaining genetic stability in the organism. These functions are realised by a series of steps known as the "p53 pathway" involving induction of the expression of a number of other genes. As p53 is the most commonly mutated gene in human cancer, it has attracted a great deal of interest in the areas of prognosis, diagnosis and therapy, and p53 gene therapy is becoming established as a useful adjunct to conventional cancer treatment.
    Original languageEnglish
    Pages (from-to)197-205
    Number of pages9
    JournalSurgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
    Issue number3
    Publication statusPublished - Jun 2005


    • Gene Expression Regulation, Neoplastic
    • Genes, p53
    • Humans
    • Mutation
    • Neoplasms


    Dive into the research topics of 'P53 in cancer: a paradigm for modern management of cancer'. Together they form a unique fingerprint.

    Cite this